OLYMPIA, Wash.–A Washington bill that would ensure the Medicaid program in the state continues covering HIV antiviral drugs ...

CRISPR technology offers innovative solutions for pandemic preparedness, enhancing diagnostics, antiviral therapies, and ...

Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...

"We are ecstatic to have W-2 back on our home planet safely and are proud to support significant reentry research for our ...

Chimerix is currently awaiting an FDA decision on accelerated approval of a drug it’s developing for a type of glioma.

Ford’s spokesperson confirmed the news, and reports from Variety and Entertainment Weekly stated that he fell ill on February ...

Health experts have warned that a new mutant strain of mpox has been discovered and it could be more infectious than current ...

More than 100 health groups in Argentina organized a country-wide mobilization against President Javier Milei’s policies, ...

David Ramos, Cascade Aids Project public policy manager, testified for the bill and said coverage for the HIV antiviral drugs is an equity issue, alongside an access issue. “Historically ...

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple effect is already being felt across biopharma.

Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal investigation.

Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisors IRDr.